11β-hydroxysteroid dehydrogenase type 1 - First part: Role of cortisol tissue exposure in the metabolic risk associated with obesity;La 11β-hydroxystéroïde déshydrogénase de type 1 - 1re partie: Rôle de l'exposition tissulaire au cortisol dans le risque métabolique lié à l'obésité

Medecine des Maladies Metaboliques

Volumn 3, Issue 5, 2009, Pages 507-513

  Iovino, A ^a   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

11 hydroxysteroid dehydrogenase type 1; Abdominal obesity; Cortisol; Glucocorticoids; Metabolic disturbances

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; CORTISONE; ENZYME; ENZYME INHIBITOR; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; LIPID; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ADIPOSE TISSUE; CUSHING DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RODENT; STEROID BLOOD LEVEL; TARGET ORGAN;

EID: 71549157437     PISSN: 19572557     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1957-2557(09)73299-7     Document Type: Article

References (33)

1. Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006;38:52-63.
2. Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review. The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009;94:2692-2701
3. Björntorp P, Rosmond R. Obesity and cortisol. Nutrition 2000;16:924-936
4. Ljung T, Ottosson M, Ahlberg AC, et al. Central and peripheral glucocorticoid receptor function in abdominal obesity. J Endocrinol Invest 2002;25:229-235 (Pubitemid 34295877)
5. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-866 (Pubitemid 39366049)
6. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-1213
7. Tomlinson JW, Stewart PM. "Cushing's disease of the omentum" - fact or fiction? J Endocrinol Invest 2004; 27:171-174
8. Vantyghem M-C, Marcelli-Tourvieille S, Defrance F, et al. 11β-hydroxystéroïde déshydrogénases. Avancées récentes. Ann Endocrinol (Paris) 2007;68:349-356
9. Müssig K, Remer T, Haupt A, et al. 11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity. Obesity (Silver Spring) 2008;16:1256-1260 (Pubitemid 351770515)
10. Walker BR, Andrew R. Tissue production of cortisol by 11β-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann NY Acad Sci 2006;1083:165-184
11. Bujalska IJ, Walker EA, Hewison M, et al. A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002;87:1205-1210 (Pubitemid 36121089)
12. Stulnig TM, Waldhäusl W. 11β-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia 2004;47:1-11. (Pubitemid 38141933)
13. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009;58:46-53.
14. Bujalska IJ, Draper N, Michailidou Z, et al. Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydoxysteroid dehydrogenase type 1. J Mol Endocrinol 2005;34:675-684 (Pubitemid 40903593)
15. Iwasaki Y, Takayasu S, Nishiyama M, et al. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11β-hydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol 2008;285:10-18
16. Nieuwenhuizen AG, Rutters F. The hypothalamic-pituitary-adrenal-axis in the regulation of energy balance. Physiol Behav 2008;94:169-177
17. Walker BR. Extra-adrenal regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning. Proc Nutr Soc 2007;66:1-8.
18. Berger J, Tanen M, Elbrecht A, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001;276:12629-12635
19. Wake DJ, Stimson RH, Tan GD, et al. Effects of peroxisome proliferator-activated receptor-α and -γ agonists on 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. J Clin Endocrinol Metab 2007;92:1848-1856
20. Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008;36:146-164
21. Swali A, Walker EA, Lavery GG, et al. 11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 2008;51:2003-2011
22. Boyle CD, Kowalski TJ. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Exp Opin Ther Pat 2009;19:801-825
23. Livingstone DE, Walker BR. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 2003;305:167-172
24. Stewart PM, Edwards CR. The cortisol-cortisone shuttle and hypertension. J Steroid Biochem Mol Biol 1991;40:501-509
25. Latif SA, Pardo HA, Hardy MP, et al. Endogenous selective inhibitors of 11β-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin. Mol Cell Endocrinol 2005;243:43-50. (Pubitemid 41572277)
26. Diederich S, Grossmann C, Hanke B, et al. In the search for specific inhibitors of human 11β-hydroxysteroid-dehydrogenases (11β-HSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-I. Eur J Endocrinol 2000;142:200-207
27. Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002;45:1528-1532 (Pubitemid 35352046)
28. Alberts P, Nilsson C, Selén G, et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycaemic mice strains. Endocrinology 2003;144:4755-4762 (Pubitemid 37378389)
29. Sundbom M, Kaiser C, Björkstrand E, et al. Inhibition of 11betaHSD1 with the S-phenylethyl aminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol 2008;8:3.
30. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005;202:517-527 (Pubitemid 41186950)
31. Lloyd DJ, Helmering J, Cordover D, et al. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab 2009;11:688-699
32. Véniant MM, Hale C, Komorowski R, et al. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes Metab 2009;11:109-117
33. Berthiaume M, Laplante M, Festuccia WT, et al. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int J Obes (Lond) 2009;33:601-604